All News

Compared with almost any other career, the path to becoming a physician requires a substantial upfront commitment of time, effort and, of course, cost. For oncology specifically, an additional ten years of training after college are required before seeing your first patient independently. In a sense, the day you finish your fellowship, you are already fully “committed.”

In a recent perspective in the New England Journal of Medicine, Richard E. Rieselbach, M.D and Arthur L. Kellerman, MD, MPH have written a proposal for how to save the community health centers (CHCs) that treat the majority of Medicaid patients from cost-cutting actions by states that need to cut their budgets.

Petri Dish is a blog written and produced by the external relations and communications staff at Fred Hutchinson Cancer Research Center. The blog delivers science and biomedical information to the world by highlighting and illuminating the scientific research at the Hutchinson Center. Reprinted with permission.

Researchers measured the rate of bankruptcy after a first cancer diagnosis and identified factors that increased bankruptcy risk among people with common cancers.

Survival for cancer patients in the United States ranks among the highest in the world.[1] Despite the demonstrated success of the US cancer delivery system, government and private payers are forcing changes to the delivery of and payment model for oncology care.

Aloe vera, a succulent plant prevalent in hot, dry regions of Asia, Africa, and other areas, has been used in traditional medicine for many centuries. It is easily propagated in most places where the climate is hot and dry.

CancerNetwork and the journal ONCOLOGY present exclusive breast cancer coverage from the annual meeting of the American Society of Clinical Oncology (ASCO). Follow the stories below and check back for more write-ups of the most important information to come out of this year's event.

It will likely not come as a surprise to anyone that the cost of cancer care is on the rise, from $104 bn in 2006 to over $173 bn in 2020. The rise in cost is driven by both the increasing cost in therapy (witness the newly approved metastatic melanoma treatment that is $120,000 for a 12-week course of therapy) and the extent of care.

One click can help millions around the world. Every new healthcare professional who creates a free account on www.cancernetwork.com will trigger our donation of $10 to the international organization Doctors Without Borders/ Mdecins Sans Frontires (MSF) - a non-profit delivering emergency medical assistance in nearly 60 countries to people affected by armed conflict, epidemics, malnutrition, natural disasters, or exclusion from health care. It's our way of promoting global social good for doctors caring for those in desperate need. Our goal is to donate $25,000 - enough for vaccinations for 25,000 people against meningitis, measles, polio or other deadly epidemics.

Your one click will help provide emergency medical care to millions of people caught in crises in nearly 60 countries around the world.

Editorial Inquiries:Anne Landry, Executive Editor Ph: 212-929-4624 Email: anne.landry@ubm.comContinuing Education: Marsha Peruo Ph: 201-984-6216 Email: marsha.peruo@cmellc.comEditorial Office: UBM Medica LLC 535 Connecticut Ave, Suite 300 Norwalk, CT 06854 Ph: 516-474-4766Publisher and Sales Contacts: Amy Birnbach Group Publisher Ph: 201-984-6265 Email: amy.birnbach@ubm.com Sarah Mifsud Account Manager Digital Media Ph: 203-523-7055 Email: sarah.mifsud@ubm.comWeb site Contact: Ian Ingram Web Editor Email: ian.ingram@ubm.com  

Paid Subscriptions: UBM Medica Healthcare Publications PO Box 390427 Minneapolis, MN 55439 Ph: 952-844-0512 Fax: 952-844-0017 Email: oncsubs@masub.com Click here to change an address or to cancel a subscription.  

OverviewONCOLOGY Nurse Edition addresses the clinical and informational needs of nurses and physician assistants working in cancer care. Scheduled publication months are February, April, July and October.Regular features in the ONCOLOGY Nurse Edition include: • Case studies • Review articles • Patient information • Drug essentials • Educational tear outsAudienceONCOLOGY Nurse Edition circulates to 8,500+ oncology nurses, advance practice nurses, and physicians assistants. Click here to view our media kit/rate card.

The journal ONCOLOGY is published monthly and is geared toward the practicing oncologist. It focuses on practical issues related to the care of patients with neoplastic disease. Topics covered may be either very broad or quite focused and, in general, are authored by a renowned expert in the particular area. Its exceptionally wide circulation within the clinical cancer community insures broad exposure of its editorial material. In addition, ONCOLOGY is included in Medline, Excerpta Medica, EMBASE, and the Cancer Line and CancerLit databases at the National Cancer Institute. Each article that appears in the journal is referred to one, two, or three reviewers, who are asked to write a short commentary to be published alongside the article. These commentaries broaden the reader's perspective on the topic being discussed as they serve to highlight areas of consensus or disagreement among professionals most familiar with the topic in question.

ONCOLOGY’s Nurse Edition publishes articles related to practical management issues in the care of patients with neoplastic disease. Through ONCOLOGY Nurse Edition, ONCOLOGY aims to provide readers with useful insights into all aspects of patient management, with an emphasis on information and tools that can be applied to daily practice and patient education.

Alisha Smallwood Licensing & Content Manager Wright's Media 2407 Timberloch Place, Suite B The Woodlands Texas 77380 Office: 281-419-5725 Toll: 877-652-5295 Fax: 281-419-5712 Email: asmallwood@wrightsmedia.comwww.wrightsmedia.com

Data from a phase II study of cabozantinib (XL184) in patients with advanced solid tumors show that the drug has activity in both bone and soft tissue. The study evaluated the efficacy and safety of cabozantinib compared to placebo in 9 different solid tumor types including breast, lung, ovarian, and prostate.

Paid Subscriptions: UBM Medica Healthcare Publications PO Box 390427 Minneapolis, MN 55439 Ph: 952-844-0512 Fax: 952-844-0017 Email: oncsubs@masub.com Click here to change an address or to cancel a subscription. 

For the past 25 years ONCOLOGY has kept pace with the progression of the oncology field and has offered an interpretation of literature which appeals to both the academician and the practicing "in-the-trenches" community oncologist. Its unique editorial platform consists of clinical and practical review articles followed by 2-3 expert commentaries. The journal's review articles are authored by top physicians in their respective specialties and address important issues and questions such as: interpretations and reviews of the latest and sometimes controversial-research; and new "takes" on persistent unresolved problems. Editorial features such as Practice & Policy, explore the changing times in the healthcare landscape in such areas as FDA regulations, Medicare & Medicaid policy, and the impact of health care reform. Another feature is Integrative Oncology which covers alternative herbal treatments, uses, research, adverse reactions and interactions. ONCOLOGY serves as a strong resource and forum for the cancer care clinician and generates a strong sense of community among its readers. Click here to view our media kit/rate card.Publisher and Sales Contacts:Amy BirnbachGroup PublisherPh: 201-984-6265Email: amy.birnbach@ubm.comSarah MifsudAccount ManagerDigital MediaPh: 203-523-7055Email: sarah.mifsud@ubm.com

A pilot mentor-to-mentor oncology nurse–led training program was developed in which volunteer former patients who have undergone brachytherapy for early stage breast cancer at UCSD were taught by the oncology nurse how to provide information and support to new patients about to undergo the procedure.

One in four Americans facing end-of-life is a veteran. Because of their traumatic experiences during combat, including experiences with death, veterans with cancer and other serious illnesses can have complex healthcare needs.

This article will present a detailed review of the body of evidence regarding the PSA assay, with reflections on the resulting future of prostate cancer screening.